vs
Side-by-side financial comparison of Ainos, Inc. (AIMD) and Dermata Therapeutics, Inc. (DRMA). Click either name above to swap in a different company.
Ainos, Inc. is the larger business by last-quarter revenue ($106.2K vs $92.8K, roughly 1.1× Dermata Therapeutics, Inc.). Dermata Therapeutics, Inc. runs the higher net margin — -1853.3% vs -3094.0%, a 1240.7% gap on every dollar of revenue. On growth, Dermata Therapeutics, Inc. posted the faster year-over-year revenue change (531.8% vs 412.4%).
Ainos, Inc. is a biotechnology firm specializing in the development and commercialization of portable point-of-care diagnostic testing solutions. Its product portfolio includes infectious disease detection kits, hormone testing tools, and general health screening products, serving clinical, consumer, and public health segments across North America, Europe, and the Asia-Pacific.
Dermata Therapeutics, Inc. is a clinical-stage biopharmaceutical firm developing novel targeted therapies for dermatological diseases including acne, psoriasis and inflammatory skin disorders. It serves U.S. patients and healthcare providers, advancing pipeline candidates through trials to address unmet dermatological care needs.
AIMD vs DRMA — Head-to-Head
Income Statement — Q1 FY2025 vs Q3 FY2023
| Metric | | |
|---|---|---|
| Revenue | $106.2K | $92.8K |
| Net Profit | $-3.3M | $-1.7M |
| Gross Margin | 82.8% | — |
| Operating Margin | -2978.0% | -1953.3% |
| Net Margin | -3094.0% | -1853.3% |
| Revenue YoY | 412.4% | 531.8% |
| Net Profit YoY | 0.9% | 29.1% |
| EPS (diluted) | $-0.21 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 25 | $106.2K | — | ||
| Q3 24 | $0 | — | ||
| Q2 24 | $0 | — | ||
| Q1 24 | $20.7K | — | ||
| Q3 23 | — | $92.8K | ||
| Q2 23 | — | $31.1K | ||
| Q1 23 | — | $37.5K | ||
| Q4 22 | — | $42.1K |
| Q1 25 | $-3.3M | — | ||
| Q3 24 | $-3.7M | — | ||
| Q2 24 | $-3.2M | — | ||
| Q1 24 | $-3.3M | — | ||
| Q3 23 | — | $-1.7M | ||
| Q2 23 | — | $-1.7M | ||
| Q1 23 | — | $-2.2M | ||
| Q4 22 | — | $-1.7M |
| Q1 25 | 82.8% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — | ||
| Q1 23 | — | — | ||
| Q4 22 | — | — |
| Q1 25 | -2978.0% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | -15051.8% | — | ||
| Q3 23 | — | -1953.3% | ||
| Q2 23 | — | -5579.4% | ||
| Q1 23 | — | -6067.3% | ||
| Q4 22 | — | -4067.0% |
| Q1 25 | -3094.0% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | -15991.2% | — | ||
| Q3 23 | — | -1853.3% | ||
| Q2 23 | — | -5479.4% | ||
| Q1 23 | — | -5967.3% | ||
| Q4 22 | — | -3967.0% |
| Q1 25 | $-0.21 | — | ||
| Q3 24 | $-1.64 | — | ||
| Q2 24 | $-2.45 | — | ||
| Q1 24 | $-0.57 | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — | ||
| Q1 23 | — | — | ||
| Q4 22 | — | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $2.6M | $6.6M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $13.1M | $6.4M |
| Total Assets | $26.4M | $7.3M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 25 | $2.6M | — | ||
| Q3 24 | $5.2M | — | ||
| Q2 24 | $8.0M | — | ||
| Q1 24 | $1.0M | — | ||
| Q3 23 | — | $6.6M | ||
| Q2 23 | — | $8.4M | ||
| Q1 23 | — | $8.8M | ||
| Q4 22 | — | $6.2M |
| Q1 25 | $13.1M | — | ||
| Q3 24 | $18.0M | — | ||
| Q2 24 | $20.7M | — | ||
| Q1 24 | $22.7M | — | ||
| Q3 23 | — | $6.4M | ||
| Q2 23 | — | $8.0M | ||
| Q1 23 | — | $8.1M | ||
| Q4 22 | — | $6.0M |
| Q1 25 | $26.4M | — | ||
| Q3 24 | $31.4M | — | ||
| Q2 24 | $35.5M | — | ||
| Q1 24 | $29.8M | — | ||
| Q3 23 | — | $7.3M | ||
| Q2 23 | — | $8.7M | ||
| Q1 23 | — | $9.3M | ||
| Q4 22 | — | $6.9M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-1.2M | — |
| Free Cash FlowOCF − Capex | $-1.3M | — |
| FCF MarginFCF / Revenue | -1184.7% | — |
| Capex IntensityCapex / Revenue | 31.7% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-6.2M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 25 | $-1.2M | — | ||
| Q3 24 | $-1.5M | — | ||
| Q2 24 | $-2.0M | — | ||
| Q1 24 | $-1.5M | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — | ||
| Q1 23 | — | $-1.6M | ||
| Q4 22 | — | $-1.8M |
| Q1 25 | $-1.3M | — | ||
| Q3 24 | $-1.5M | — | ||
| Q2 24 | $-2.0M | — | ||
| Q1 24 | $-1.5M | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — | ||
| Q1 23 | — | — | ||
| Q4 22 | — | — |
| Q1 25 | -1184.7% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | -7232.3% | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — | ||
| Q1 23 | — | — | ||
| Q4 22 | — | — |
| Q1 25 | 31.7% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 21.4% | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — | ||
| Q1 23 | — | — | ||
| Q4 22 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
